Sexual Health Sexual Health Society
Publishing on sexual health from the widest perspective

Human papillomavirus vaccine safety in Australia: experience to date and issues for surveillance

Michael S. Gold A D , Jim Buttery B and Peter McIntyre C

A Discipline of Paediatrics, School of Paediatrics and Reproductive Health, University of Adelaide, SA 5001, Australia.

B SAEFVIC, Department of General Medicine, Murdoch Children’s Research Institute, Royal Children’s Hospital Melbourne and Infectious Diseases Unit, Department of Paediatrics, Monash Children’s Hospital, Monash University, Melbourne, Parkville, Vic 3052, Australia.

C The National Centre for Immunisation Research, The Children’s Hospital at Westmead, Locked Bag 4001, Westmead, NSW 2145, Australia.

D Corresponding author. Email:

Sexual Health 7(3) 320-324
Submitted: 29 December 2009  Accepted: 23 March 2010   Published: 19 August 2010


Australia was one of the first countries to licence a quadrivalent human papillomavirus (HPV) vaccine, rapidly followed by a federally funded program of universal vaccination of a broad age group of females through schools (12 to 18 years) and primary care (19 to 26 years). As of August 2009, more than 5.8 million doses of Gardasil® (quadrivalent; Merck, New Jersey, USA) have been distributed in Australia and a total of 1394 suspected adverse events following immunisation (AEFI) have been reported to the passive surveillance system. Most reports are of common and expected reactions. Case series of more uncommon and serious AEFI, both known to be potentially vaccine related (anaphylaxis, conversion disorders and lipoatrophy) and otherwise (multiple sclerosis and pancreatitis) have been published.

Additional keywords: adverse events following immunisations, HPV vaccine, vaccine safety.


[1]  Australian Government Department of Health and Ageing, Therapeutic Goods Administration. Human papillomavirus vaccine (GARDASIL). 2009. Available online at: [verified November 2009].

[2]  Anonymous Scientific Discussion 2006. Available online at: [verified November 2009].

[3]  Postila V 2004 Sample size required for detecting at least one case of an adverse event with different incidence rates. Vaccine 22 2076 9 doi:10.1016/j.vaccine.2004.01.020

[4]  Aide Memoire on AEFI investigation. Available online at: [verified May 2010]

[5]  Lawrence G Gold MS Hill R Deeks S Glasswell A McIntyre PB 2008 Annual report: surveillance of adverse events following immunisation in Australia, 2007. Commun Dis Intell 32 371 87

[6]  Menzies R Mahajan D Gold MS Roomiani I McIntyre P Lawrence G 2009 Annual report: surveillance of adverse events following immunisation in Australia, 2008. Commun Dis Intell 33 365 81

[7]  Brotherton JM Gold MS Kemp AS McIntyre PB Burgess MA Campbell-Lloyd S et al 2008 Anaphylaxis following quadrivalent human papillomavirus vaccination. CMAJ 179 525 33

[8]  Buttery JP Madin S Crawford NW Elia S La Vincente S Hanieh S et al 2008 Mass psychogenic response to human papillomavirus vaccination. Med J Aust 189 261 2

[9]  Ojaimi S Buttery JP Korman TM 2009 Quadrivalent human papillomavirus recombinant vaccine associated lipoatrophy. Vaccine 27 4876 8

[10]  Sutton I Lahoria R Tan I Clouston P Barnett M 2009 CNS demyelination and quadrivalent HPV vaccination. Mult Scler 15 116 9 doi:10.1177/1352458508096868

[11]  Kang LW Crawford N Tang ML Buttery J Royle J Gold M et al 2008 Hypersensitivity reactions to human papillomavirus vaccine in Australian schoolgirls: retrospective cohort study. BMJ 337 a2642 doi:10.1136/bmj.a2642

[12]  Das A Chang D Biankin AV Merrett ND 2008 Pancreatitis following human papillomavirus vaccination. MJA 189 178

[13]  Slade BA Leidel L Vellozzi C Woo EJ Hua W Sutherland A et al 2009 Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 302 750 7

[14]  Rüggeberg JU Gold MS Bayas JM Blum MD Bonhoeffer J Friedlander S et al 2007 Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine 25 5675 84 doi:10.1016/j.vaccine.2007.02.064

[15]  D’Souza RM Campbell-Lloyd S Isaacs D Gold M Burgess M Turnbull F et al 2000 Adverse events following immunisation associated with the 1998 Australian measles control campaign. Commun Dis Intell 24 27 33

[16]  Siegrist CA Lewis EA Eskola J Evans S Black SB 2007 Human papillomavirus immunization in adolescent and young adults: a cohort study to illustrate what events might be mistaken for adverse reactions. Pediatr Infect Dis J 26 979 84

[17]  Lucas RM Ponsonby AL McMichael AJ van der Mei I Chapman C Coulthard A et al 2007 Observational analytic studies in multiple sclerosis: controlling bias through study design and conduct. The Australian Multicentre Study of Environment and Immune Function. Mult Scler 13 827 39 doi:10.1177/1352458507077174

[18]  Tourbah A Gout O Liblau R Lyon-Caen O Bougniot C Iba-Zizen MT Cabanis EA 1999 Encephalitis after hepatitis B vaccination: recurrent disseminated encephalitis or MS? Neurology 53 396 401

[19]  DeStefano F Verstraeten T Chen RT 2002 Hepatitis B vaccine and risk of multiple sclerosis. Expert Rev Vaccines 1 461 6

[20]  Watson M Shaw D Molchanoff L McInnes C 2009 Challenges, lessons learned and results following the implementation of a human papillomavirus school vaccination program in South Australia. Aust NZ J Public Health 33 365 70 doi:10.1111/j.1753-6405.2009.00409.x

[21]  Brotherton JM Deeks SL Campbell-Lloyd S Misrachi A Passaris I Peterson K et al 2008 Interim estimates of human papillomavirus vaccination coverage in the school-based program in Australia. Commun Dis Intell 32 457 61

Export Citation